Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 1 ( January-March, 2016 ) > List of Articles

RESEARCH ARTICLE

J-Curve Phenomenon—Current Understanding and Clinical Implications

T Govindan Unni

Keywords : Curve,Hypertension,Hypoperfusion

Citation Information : Unni TG. J-Curve Phenomenon—Current Understanding and Clinical Implications. Hypertens J 2016; 2 (1):16-20.

DOI: 10.5005/jp-journals-10043-0024

Published Online: 00-03-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Unni TG. J-Curve Phenomenon—Current Understanding and Clinical Implications. Hypertens J 2016;2(1):16-20.


PDF Share
  1. Heart disease. 1st ed. New York, NY: McMillan; 1931.
  2. Practice of medicine. 1st ed. Hagerstown, MD: WF Prior Company, Inc.; 1924.
  3. Isolated systolic hypertension and the J-curve of cardiovascular disease risk. Artery Res 2010 Mar;4(1):1-6.
  4. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham heart study. Circulation 2009 Jan 20;119(2):243-250.
  5. High blood pressure. 2nd ed. London: Churchill; 1968.
  6. It is all about flow or, why there will never be one optimal blood pressure goal for every patient with hypertension. J Clin Hypertens (Greenwich) 2011 Jun;13(6):395-396.
  7. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979 Apr 21;1(8121):861-865.
  8. Benefits and potential harm of lowering blood pressure. Lancet 1987 Mar 14;1(8533):581-584.
  9. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13;351(9118): 1755-1762.
  10. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomizedtrial. Lancet 2004 Jun 19;363(9426):2022-2031.
  11. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: the VALUE trial. Blood Press. 2015 Oct 29:1-10.
  12. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.
  13. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009 Jul;27(7):1360-1369.
  14. The ACCORD study group: effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 Apr 29;362(17):1575-1585.
  15. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015 Nov 26;373(22):2103-2116.
  16. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2015 Dec 23.
  17. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006 Jun;24(6):1201-1208.
  18. PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011 Nov 16;306(19):2137-2144.
  19. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005 May;45(5):907-913.
  20. A likely explanation for J curve of blood pressure cardiovascular risk. Am J Cardiol 2004 Aug;94(3):3804.
  21. Dogma disputed: can aggressively lowering blood pressure for hypertension in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006 Jun 20;144(12):884-893.
  22. Hypertension and the J-Curve. J Am Coll Cardiol 2009;54(20):1835-1836.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.